Abstract
Objectives We evaluated the clinical, virological and safety outcomes of lopinavir/ritonavir, lopinavir/ritonavir-interferon (IFN)-β-1a, hydroxychloroquine or remdesivir in comparison to standard of care (control) in COVID-19 inpatients requiring oxygen and/or ventilatory support. While preliminary results were previously published, we present here the final results, following completion of the data monitoring.
Methods We conducted a phase 3 multi-centre open-label, randomized 1:1:1:1:1, adaptive, controlled trial (DisCoVeRy), add-on trial to Solidarity (NCT04315948, EudraCT2020-000936-23). The primary outcome was the clinical status at day 15, measured by the WHO 7-point ordinal scale. Secondary outcomes included SARS-CoV-2 quantification in respiratory specimens, pharmacokinetic and safety analyses. We report the results for the lopinavir/ritonavir-containing arms and for the hydroxychloroquine arm, which were stopped prematurely.
Results The intention-to-treat population included 593 participants (lopinavir/ritonavir, n=147; lopinavir/ritonavir-IFN-β-1a, n=147; hydroxychloroquine, n=150; control, n=149), among whom 421 (71.0%) were male, the median age was 64 years (IQR, 54-71) and 214 (36.1%) had a severe disease. The day 15 clinical status was not improved with investigational treatments: lopinavir/ritonavir versus control, adjusted odds ratio (aOR) 0.82, (95% confidence interval [CI] 0.54-1.25, P=0.36); lopinavir/ritonavir-IFN-β-1a versus control, aOR 0.69 (95%CI 0.45-1.05, P=0.08); hydroxychloroquine versus control, aOR 0.94 (95%CI 0.62-1.41, P=0.76). No significant effect of investigational treatment was observed on SARS-CoV-2 clearance. Trough plasma concentrations of lopinavir and ritonavir were higher than those expected, while those of hydroxychloroquine were those expected with the dosing regimen. The occurrence of Serious Adverse Events was significantly higher in participants allocated to the lopinavir/ritonavir-containing arms.
Conclusion In adults hospitalized for COVID-19, lopinavir/ritonavir, lopinavir/ritonavir-IFN-ß-1a and hydroxychloroquine did not improve the clinical status at day 15, nor SARS-CoV-2 clearance in respiratory tract specimens.
Introduction
Worldwide research efforts against SARS-CoV-2 initially focused on repurposed drugs that showed broad-spectrum antiviral activity against coronaviruses (1,2). Lopinavir/ritonavir (3,4), type I interferon (IFN) (5–7), hydroxychloroquine (8–10), and remdesivir (11) were among the first investigational treatments to be tested on the basis of their in vitro activity against SARS-CoV-2.
The DisCoVeRy trial is a European randomized controlled trial evaluating the clinical and the virological efficacy, as well as the safety, of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a, hydroxychloroquine, and remdesivir as compared with standard of care in adults hospitalized for COVID-19 (12). As an add-on trial to the international Solidarity trial sponsored by the World Health Organization (WHO), it has contributed to data acquisition on in-hospital mortality, need for mechanical ventilation and time to hospital discharge. Interim analyses of these variables concluded to futility, leading to discontinuation of three treatment arms while inclusions continued in the remdesivir arm (13). The DisCoVeRy trial was designed to further document clinical outcomes, virological kinetics, treatment pharmacokinetics and related safety data. We report here the final results for the lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine arms, after completion of the data monitoring. Preliminary results were previously published (14). Results for the remdesivir arm have been presented separately (15).
Methods
Trial design and oversight
DisCoVeRy is a phase 3 open-label, adaptive, multicenter, randomized, superiority-controlled trial which evaluates the efficacy and safety of repurposed drugs in adults hospitalized for COVID-19. Sponsored by the Institut national de la santé et de la recherche médicale (Inserm, France), the trial was approved by the Ethics Committee (CPP Ile-de-France-III, approval #20.03.06.51744). Written informed consent was obtained from all included participants or their legal representative, when unable to consent. The trial was conducted in accordance with the Declaration of Helsinki and national laws and regulations and declared on the clinicatrials.gov registry (NCT 04315948) and on the European Clinical Trials Database (2020-000936-23).
Study population
Eligible participants were adults (≥ 18-year-old) hospitalized with a PCR-positive (< 72 hours) SARS-CoV-2 infection and pulmonary rales or crackles with a peripheral oxygen saturation ≤ 94% or requiring supplemental oxygen. Inclusion and exclusion criteria are presented in the Supplementary Appendix.
Interventions and randomization
Participants were randomly assigned to treatment arms in a 1:1:1:1 ratio, through computer-generated blocks of various sizes and stratification by administrative region and severity of disease at enrolment (moderate: hospitalized participants not requiring oxygen or receiving low-flow supplemental oxygen; severe: hospitalized participants requiring non-invasive ventilation or high-flow oxygen devices, invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)). Randomization was implemented in the electronic Case Report Form to ensure appropriate allocation concealment. Investigational arms were standard of care (SoC, control), SoC plus lopinavir/ritonavir (400 mg lopinavir and 100 mg ritonavir orally twice on day for 14 days (3,16)), SoC plus lopinavir/ritonavir plus IFN-ß-1a (44 μg of subcutaneous IFN-ß-1a on days 1, 3, and 6), SoC plus hydroxychloroquine (400 mg orally, twice on day 1 as a loading dose followed by 400 mg once daily for 9 days) (17). Supportive treatments corticosteroids, anticoagulants or immunomodulatory agents were allowed except antivirals. Enrolment in another investigative trial was not allowed.
Clinical and laboratory monitoring
Participants were assessed at days 3, 5, 8, 11, 15±2 and 29±3 while hospitalized. If discharge occurred before day 15, face-to-face visits were set up for days 15±2 and 29±3, for efficacy and safety evaluations. Clinical data, concomitant medications, adverse events (AEs) and measurements for safety biological data (blood cell counts, serum creatinine and liver aminotransferases) were collected. Nasopharyngeal swab (NPS) and lower respiratory tract (LRT) specimens were collected for SARS-CoV-2 RNA quantification. For lopinavir and ritonavir, trough plasma concentrations were obtained at days 1 and 3, 12h (±2h) after the last administration and for hydroxychloroquine, at day 1 12h (±2h) and at day 3 24h (±4h) after the last administration.
Outcomes measures
The primary outcome measure was the clinical status at day 15 as measured on the 7-point ordinal scale of the WHO Master Protocol (v3.0, March 3, 2020): 1. Not hospitalized, no limitation on activities; 2. Not hospitalized, limitation on activities; 3. Hospitalized, not requiring supplemental oxygen; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, on non-invasive ventilation or high flow oxygen devices; 6. Hospitalized, on invasive mechanical ventilation or ECMO; 7. Death.
Secondary efficacy outcome measures were the clinical status at day 29 and the time to an improvement of 2 categories as measured on the 7-point ordinal scale or hospital discharge until day 29, the time to National Early Warning Score 2 (NEWS2) ≤2 or hospital discharge until day 29, the time to hospital discharge until day 29, oxygenation- and ventilator-free days until day 29, in-hospital, 29-day and 3-month mortality, and the SARS-CoV-2 detection and quantitative normalized viral loads. Trough plasma concentrations of lopinavir, ritonavir and hydroxychloroquine were measured at days 1 and 3.
Secondary safety outcomes included the cumulative incidence of any grade 3 or 4 AE, or of any serious adverse event (SAE, according to the DAIDS Table for Grading the Severity of Adult and Paediatric Adverse Events, v2.1, July 2017) and the proportion of patients with a premature suspension or discontinuation for any reason of the investigational treatments.
Virological methods
Determination of normalized viral load blinded to treatment arm was performed on NPS and LRT specimens by RNA extraction on the EMAG® platform (bioMerieux, Marcy-l’Étoile, France). The SARS-CoV-2 load was measured by quantitative RT-PCR, according to a scale of calibrated in-house plasmid, using the RT-PCR RdRp-IP4 developed by the Institut Pasteur (Paris, France) (18). The amplification protocol was developed using QuantStudio 5 rtPCR Systems (Thermo Fisher Scientific, Waltham, Massachusetts, USA). The number of cells in sample (quality criteria for NPS and normalization tool for viral load determination) was checked using the CELL Control r-gene® kit (Argene-BioMérieux, Marcy-l’Étoile, France). If cell quantification was below 500 cells/reaction, the quality of the sample was considered too low to be measured. We computed a normalized SARS-CoV-2 load by dividing the viral load by the number of cells. All viral loads strictly below 1 log10 RNA copies/10 000 cells were considered under the limit of detection and were reported as negative.
Pharmacological methods
Plasma concentrations of lopinavir, ritonavir and hydroxychloroquine were determined using liquid chromatography coupled with tandem mass spectrometry (19,20). The limits of quantification were 30 ng/mL for lopinavir and ritonavir, and 10 ng/mL for hydroxychloroquine.
Sample size calculation
The sample size was determined assuming the following scenario under SoC for each item of the ordinal scale at day 15: 1, 42%; 2, 38%; 3, 8%; 4, 7%; 5, 2%; 6, 1%; 7, 2%. At the time of the trial design, there was a significant uncertainty with these assumptions. We powered the study for an odds ratio of 1.5 (an odds ratio higher than 1 indicates superiority of the experimental treatment over the control for each ordinal scale category), with 90% power and using an overall two-sided type I error rate of 0.05. Adjusting for multiplicity of 4 pairwise comparisons with the control arm in a 5-arm setting, the two-sided false positive error rate would be 0.0125. We determined that the inclusion of 620 patients in each treatment arm was required.
Statistical and interim analyses
An independent data safety and monitoring board (DSMB) externally reviewed the trial data periodically. Based on interim analyses (see Supplementary Appendix), enrolment in the hydroxychloroquine arm was prematurely stopped on June 17th, and enrolment in lopinavir-containing arms was stopped on June 29th 2020.
For the 7-point ordinal scale, data were analyzed using a proportional odds model, which assumes a common odds ratio between the 7 points of the ordinal scale. All analyses were stratified by severity at randomization, and adjusted effect measures are reported. Full statistical methods are presented in Supplementary Appendix.
Results
Patient’s characteristics at baseline
Between March 22nd and June 29th 2020, 603 participants were randomized across 30 sites in France and 2 in Luxembourg; 593 were evaluable for analysis (Supplementary Figure S1): control arm, n=149; lopinavir/ritonavir arm, n=147; lopinavir/ritonavir plus IFN-ß-1a arm, n=147; hydroxychloroquine arm, n=150. Participants’ baseline characteristics are presented in Table 1. Participants were mostly male (n=421, 71.0 %), median age was 64 years (IQR, 54-71). The median time from symptoms onset to randomization was 9 days (IQR, 7-12). The most frequent underlying conditions were obesity (n=169, 28.7%), chronic cardiac disease (n=155, 26.2 %) and diabetes mellitus (n=134, 22. 7%). At baseline, severe disease accounted for 214 (36.1%) participants. Concomitant treatments are listed in Supplementary Table 1.
NPS, Nasopharyngeal swabs; LRT, Lower respiratory tract.
* denotes variables with missing data. Data on chronic cardiac disease, chronic pulmonary disease, mild liver disease, chronic neurological disorder, active cancer and diabetes mellitus were missing for 2 patients; data on chronic kidney disease were missing for 3 patients; data on auto-inflammatory disease were missing for 1 patient; data on obesity were missing for 5 patients; data on smoking status were missing for 29 patients; data on the time from symptoms onset to randomization were missing for 7 patients; data on BMI were missing for 80 patients; data on randomization site were missing for 1 patient; data on viral load from NPS were missing for 236 patients; data on viral load from LRT specimens were missing for 538 patients; data for lymphocyte count were missing for 93 patients; data for neutrophil count were missing for 140 patients; data on creatinine were missing for 9 patients; data on AST/SGOT were missing for 40 patients; data on ALT/SGPT were missing for 37 patients; data on CRP were missing for 133 patients; data on D-Dimers were missing for 304 patients; data on PCT were missing for 362 patients; data on ferritin were missing for 426 patients.
** moderate disease: hospitalized participants receiving low-flow supplemental oxygen or not requiring oxygen; severe disease: hospitalized participants requiring non-invasive ventilation or high-flow oxygen devices, invasive mechanical ventilation or ECMO
Primary endpoint
The distribution of the 7-point ordinal scale at day 15 is presented in Figure 1 and Table 2. Adjusted OR for clinical improvement (aOR) were not in favor of investigational treatments (i.e., below 1): lopinavir/ritonavir versus control, aOR 0.82 (95% confidence interval [CI] 0.54-1.25, P=0.36); lopinavir/ritonavir plus IFN-ß-1a vs. control, aOR 0.69 (95%CI 0.45-1.05, P=0.08); hydroxychloroquine vs. control, aOR 0.94 (95%CI 0.62-1.41, P=0.76).
Analyses were stratified on the disease severity at baseline (moderate: 7-point ordinal scale 3 or 4; severe: 7-point ordinal scale 5 or 6), and adjusted effect measures are reported in the table. NP, Nasopharyngeal; LRT, Lower respiratory tract; OR, Odds-ratio; HR, Hazard ratio; LSMD, least-square mean difference.
Reported numbers refer to the proportion of patients with the corresponding level in each group. L/r, Lopinavir/ritonavir; L/r + IFN, Lopinavir/ritonavir + interferon ß-1a; HCQ, Hydroxychloroquine.
Secondary endpoints
There was no significant difference between any of the treatment and control arms on the 7-point ordinal scale at day 29 (Figure 1 and Table 2). The time to improvement of 2 categories of the same scale or hospital discharge within day 29 was significantly longer in lopinavir/ritonavir-containing arms than in the control arm: lopinavir/ritonavir versus control, HR=0.70 (95%CI 0.54-0.92, P=0.01 and lopinavir/ritonavir plus IFN-ß-1a versus control, HR=0.68 (95%CI 0.52-0.89, P=0.008). The time to NEWS ≤2 or hospital discharge within 29 days was significantly longer in the lopinavir/ritonavir plus IFN-ß-1a arm than in the control arm (HR=0.72, 95%CI 0.54-0.96, P=0.02), as was the time to hospital discharge within day 29 (HR=0.72, 95%CI 0.54-0.97, P=0.03). Participants assigned to the lopinavir/ritonavir plus IFN-ß-1a arm exhibited a higher risk of 3-month mortality than participants assigned to the control arm: aOR 2.11 (95%CI 1.01;4.39, P=0.04), while no significant effect was observed in the lopinavir/ritonavir arm (aOR 1.41, 95%CI 0.65;3.06, P=0.39) nor in the hydroxychloroquine arm (aOR 1.17, 95%CI 0.53;2.58, P=0.70).
No other significant difference was observed for other secondary outcomes (Table 2 and Supplementary Figures S2-S4).
Virological endpoints
The slope of the decrease of the viral loads in NPS over time was not significantly affected by any of the investigational treatments (Figure 2). No significant difference in the proportion of participants with detectable viral loads at each sampling time was observed in the NPS nor in the LRT specimens (Supplementary Table S2 and S3).
L/r, Lopinavir/ritonavir (blue line); L/r + IFN, Lopinavir/ritonavir + interferon ß-1a (yellow line);
HCQ, Hydroxychloroquine (red line); control (black line).
LSMD, least-square mean difference; 95%CI, 95% confidence interval.
Trough concentrations of experimental treatments
At day 3, median trough plasma concentrations of lopinavir were 20 328 ng/mL (IQR, 13 251; 26 980) and 20 926 ng/mL (16 510; 25 930) and of ritonavir were 536 ng/mL (312; 1 028) and 609 ng/mL (388; 1 164) in the lopinavir/ritonavir and in the lopinavir/ritonavir plus IFN-β-1a, respectively (Supplementary Table S4). Median trough plasma concentrations of hydroxychloroquine were 126 ng/mL (67; 276).
Safety
The safety analysis included 589 participants (control, n=149; lopinavir/ritonavir, n=147; lopinavir/ritonavir plus IFN-β-1a, n=145; hydroxychloroquine, n=148). Safety outcomes are presented in Table 3. Among 2524 reported AEs, 570 were graded 3 or 4 in 243 patients and mostly reported in lopinavir/ritonavir-containing arms (Table 3).
In the “Overall” column, numbers refer to number of events and number of patients. In other columns, number refer to number of patients (%). Some patients had more than a single SAE. Analyses were performed on the modified Intention-to-treat population. SAE, Serious Adverse Event. P-value refer to Fisher exact test.
* According to the investigator’ judgement. Among participants with the occurrence of the SAE related to the experimental treatment, 16 (44.4%) in the lopinavir/ritonavir arm, 36 (65.4%) in the lopinavir/ritonavir plus INF-β-1a arm and 13 (44.8%) in the hydroxychloroquine arm discontinued the experimental treatment.
** Including renal failure in 30 patients, hepatic disorders in 25 patients and electrocardiogram abnormalities in 9 patients. IFN treatment was completed in all patients from the Lopinavir/ritonavir + Interferon ß-1a arm.
*** Excluding acute renal failures defined based on the RIFLE classification.
A total of 856 SAEs were reported in 282 participants; 189 (22.1%) were related to the investigational drug according to investigator’s judgment (lopinavir/ritonavir arm, n=54 lopinavir/ritonavir plus IFN-β-1a arm, n=89; hydroxychloroquine arm, n=46). A significantly greater number of patients experienced at least one SAE in the lopinavir/ritonavir-containing arms than in the control arm (Table 3). The most frequently reported SAEs were acute respiratory failure (n=78, 13.2%), acute kidney injury (n=64, 10.8%), acute respiratory distress syndrome (n=74, 12.5%), arrhythmia (n=58, 9.4%), pulmonary embolism (n=34, 55.7%), and sepsis including those related to super-infections (n=32, 5.4%). Twelve percent (n=103) of participants developed at least one kidney-related SAE. Among them, 23 had acute renal failure upon admission, and 78 were critically-ill ventilated patients with acute kidney injury. Among 64 fatal SAEs, 32 had a pulmonary origin, and 32 had a non-pulmonary origin. Three non-pulmonary-related deaths were linked to investigational treatments by investigators, all in the - lopinavir/ritonavir plus IFN-ß-1a arm.
Discussion
We report here the results of the DisCoVeRy clinical trial, evaluating lopinavir/ritonavir with or without IFN-ß-1a, or hydroxychloroquine in comparison with control for the treatment of inpatients with COVID-19. Participants had mostly moderate disease (63.9%) covering a large spectrum of clinical presentations. Inclusions were prematurely stopped for futility, so that the number of included patients is lower than the estimated sample size. Consistently with Solidarity results, investigational treatments failed to improve the clinical course of COVID-19. No effect on SARS-CoV-2 clearance was observed, using a reproducible normalized method. Furthermore, significantly more SAEs were reported in the lopinavir/ritonavir-containing arms than in the control arm.
Two randomized trials conducted in hospitalized COVID-19 patients found no benefit of lopinavir/ritonavir in terms of 28-day mortality or of progression to mechanical ventilation or death (9,21). No added benefit was observed using IFN-ß-1a, as the median time to randomization of 9 days may have been too long to allow an immune-mediated boosting effect on viral clearance. We observed plasma overexposure of lopinavir relative to target concentrations obtained in HIV-infected patients, possibly responsible for the higher rate of SAEs and more acute kidney injury than controls. The SARS-CoV-2-induced inflammatory burden may have reduced Cytochrome P450 activity and modified plasma α-1-acid glycoprotein levels, an acute phase protein which binds protease inhibitors (22,23). Reported in-vitro half maximal inhibitory concentration (EC50) for SARS-CoV2 is 16,400 ng/mL (24) (while the EC50 for HIV is 70 ng/mL (25)), an over 200-fold difference, suggesting that significantly higher concentrations of lopinavir are needed to enhance SARS-CoV-2 clearance. A recent physiologically-based pharmacokinetic model suggested that standard regimens of lopinavir/ritonavir are not sufficient to achieve efficacy through unbound lung concentrations (26). In our study, trough lopinavir plasma concentrations at day 3 were more than 2-fold higher than expected with the standard dose (27), but were below the EC50 of SARS-CoV2 in 25% of participants.
Several larger-scale randomized controlled trials conducted in hospitalized COVID-19 patients failed to demonstrate the clinical efficacy of hydroxychloroquine (28,29). Our results are in line with these conclusions. We report that hydroxychloroquine does not accelerate SARS-CoV-2 clearance, consistent with preclinical data (30). Based on in vitro EC50 against SARS-CoV-2 (242 ng/mL), the target plasma concentration was reached in only 25% of participants at day 3, and optimal intrapulmonary exposure might have been only achieved at day 10 (10,17). It could be argued that the dosing regimen administered in the DisCoVeRy trial was insufficient to rapidly reach target concentrations. However, Solidarity and Recovery trials, which both used a doubled hydroxychloroquine dosing regimen, did not bring evidence of clinical benefit either (13,29).
The trial has limitations: the complexity of blinding treatments with different routes of administration and the need to initiate the trial very rapidly led to choose an open-labelled design. The trial did not target patients at the early phase of the disease nor include arms testing anti-inflammatory agents that could be used as part of the SoC in any arm. In addition, the trial was performed in the early phase of the COVID-19 pandemics and the SoC underwent substantial changes over time, adapting to knowledge acquisition, especially regarding the use of corticosteroids in COVID-19.
Conclusion
In patients admitted to hospital with COVID-19, lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine were not associated with clinical improvement at day 15 and day 29, nor reduction in viral shedding, and generated significantly more SAEs in lopinavir/ritonavir-containing arms. These findings do not support the use of these investigational treatments for patients hospitalized with COVID-19.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Authors contribution
Writing – Original Draft: FA, CB; Writing – Review & Editing: NPS, JP, MBD, DB, ADi, MH, MPL, GP, DC, YY, FM; Conceptualization: FA, NPS, JP, MBD, GP, BL, DC, YY, FM; Investigation: FA, NPS, JP, MBD, Adi, NM, FXL, FR, FG, AK, SJ, JR, SN, FD, RCJ, KB, JCN, VT, AC, CDu, JC, SL, JM, RG, BM, EF, VP, SG, OL, KL, JPL, AM, GMB, LB, ÉBN, AGB, OE, LP, FW, JCR, JR, TS, MH, CA, MPL, GP; Methodology: FA, NPS, JP, MBD, DC, CB, FM; Data curation: ADi, ADe, NM, ADu, TA; Formal Analysis: DB, ADu, DC, CB, FM
Project Administration: FA, CD, FM; Funding Acquisition: FA, CDe, JS, DC, YY, FM.
Funding
The study was funded by Programme Hospitalier de Recherche Clinique (PHRC-20-0351) (Ministry of Health), from the DIM One Health Île-de-France (R20117HD), and from REACTing, a French multi-disciplinary collaborative network working on emerging infectious diseases. Sanofi provided hydroxychloroquine, AbbVie provided lopinavir/ritonavir and Merck provided IFN-β-1a, all free of charge. The funding sources had no role in the analysis of the data nor in the decision of publication.
Declaration of interests
F.R. reports personal fees from Gilead Sciences, personal fees from MSD, personal fees from Pfizer, personal fees from TheraTechnologies, personal fees from ViiV Healthcare, outside the submitted work. F.G. reports grants from BioMerieux, personal fees and non-financial support from Gilead, non-financial support from Corevio, outside the submitted work. G.P. reports grants and personal fees from Gilead Sciences, grants and personal fees from Merck, grants and personal fees from ViiV Healthcare, grants and personal fees from TheraTechnologies, outside the submitted work. K.L. reports personal fees and non-financial support from Gilead, personal fees and non-financial support from Janssen, personal fees and non-financial support from MSD, personal fees and non-financial support from ViiV Healthcare, personal fees and non-financial support from Abbvie, during the conduct of the study. Y.Y. has nothing to disclose. He has been a board member receiving consultancy fees from ABBVIE, BMS, Gilead, MSD, J&J, Pfizer, and ViiV Healthcare, however all these activities have been stopped in the 03 past years. F.L. reports personal fees from Gilead, personal fees and non-financial support from MSD, non-financial support from Astellas, non-financial support from Eulmedica, outside the submitted work. A.K. reports personal fees from Baxter, personal fees from Aspen, personal fees from Aguettant, outside the submitted work. S.N. reports personal fees from MSD, personal fees from Pfizer, personal fees from Gilead, personal fees from Biomérieux, personal fees from BioRad, outside the submitted work. F.D. reports personal fees from Gilead, outside the submitted work. J.N. reports non-financial support from MSD France, non-financial support from GILEAD Sciences, personal fees from PASCALEO, outside the submitted work. J.M. reports non-financial support from GILEAD, outside the submitted work. A.M. reports personal fees from MSD, personal fees from GILEAD, personal fees from JANSSEN, personal fees from Viiv Healthcare, outside the submitted work. M.H. reports grants from Fonds Erasme-COVID-Université Libre de Bruxelles, grants from Belgian health Care Knowledge Center, during the conduct of the study; personal fees from Gilead advisory board on education on invasive fungal infections, personal fees from Pfizer: moderator for session on Isavuconazole, outside the submitted work. D.C. reports personal fees from Gilead, grants and personal fees from Janssen, outside the submitted work. C.B. reports personal fees from Da Volterra, personal fees from Mylan Pharmaceuticals, outside the submitted work. F.M. reports grants from Sanofi, grants and personal fees from Da Volterra, outside the submitted work. All other authors have nothing to disclose.